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One of the most serious health problems affecting women is breast
cancer. The incidence of breast cancer has risen at an alarming rate
over the past 40 years. Breast cancer-associated deaths will rise to
500 000 every year by the year 2000 (Pisani et al, 1985). Recent
studies have shown that inherited or sporadic mutation in the
breast cancer susceptibility genes BRCA1 and BRCA2 account for
45% of increased incidence of the disease. The mechanisms asso-
ciated with the loss of function of these genes and its correlation
with disease incidence is not exactly known, due primarily to the
absence of knowledge pertaining to their function. Therefore, the
identification and use of novel approaches for the prevention and
detection of breast cancer are urgently needed.
KLK3, commonly known as prostate specific antigen (PSA), is
an established marker for prostate cancer (Stamey et al, 1987;
Catalona et al, 1991). It was originally identified as a tissue-
specific protein expressed exclusively by the epithelial cells of the
prostate gland (Oesterling, 1991). Recently, improved ultrasensi-
tive methods and RNA analysis has shown that KLK3 (PSA) is not
exclusively synthesized by the human prostate gland, but also
found to be produced by the breast, ovary, liver, kidney, adrenal
and parotid glands (Levesque et al, 1995; Smith et al, 1995). With
ultrasensitive immunofluorometric PSA assays, which have a
detection limit of 1 ng l–1, it has been observed that > 50% of
female sera have detectable PSA concentration (Ferguson et al,
1996). PSA can be measured in ~70% of breast cancer cytosolic
extracts (Ferguson et al, 1996). A number of human breast cancer
cell lines have also been described to express this glycoprotein in a
hormone-dependent manner (Yu et al, 1994; Zarghami et al, 1997).
The human kallikrein gene family consists of three members:
prostate specific antigen (PSA; KLK3), glandular kallikrein
(GK-1; KLK2) and pancreatic/renal kallikrein (KLK1) (Schedlich
et al, 1987; MacDonald et al, 1988; Digby et al, 1989; Riegman et
al, 1989). These three genes are clustered in an area of 60 kb on
human chromosome 19q13.2–13.4 (Riegman et al, 1992). PSA, a
kallikrein-like protease, was originally found to be synthesized by
normal, hyperplastic and malignant prostatic epithelium, and is
thought to be required for the liquefaction of seminal clot after
ejaculation (Lilja, 1985; Watt et al, 1986). PSA exists primarily in
two immunoreactive forms: a ~ 30-kDa monomer (free PSA)
and a ~100-kDa complex with the protease inhibitor a1-anti-
chymotrypsin (PSA-ACT) (McCormak et al, 1995).
The PSA gene consists of five functionally coded exons with an
open reading frame of 257 amino acids encoding a protein with a
predicted molecular weight of ~30 kDa. The promoter and the
enhancer elements of the PSA gene have been extensively charac-
terized (Schuur et al, 1996; Cleutjens et al, 1997). The 5¢ flanking
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portion of the gene is approximately 6 kb long and located 12 kb
upstream of the hGK-1 gene. The PSA gene is under regulation by
steroid hormones. Studies have shown that under physiological
and pathological situations, PSA production is a steroid hormone
receptor-mediated response. Others have shown that the wild-type
PSA gene is regulated by the androgen receptor (AR), mediating
transcription by binding to its cognate sequence on the PSA
proximal promoter at position –154 and –394 (Schuur et al, 1996).
In addition, a third androgen response element (ARE) is located in
the distal enhancer at position –4200 (Cleutjens et al, 1997). The
proximal and the distal enhancer of the PSA gene interact in a
cooperative manner and are required for optimal expression of the
gene (Riegman et al, 1991; Schuur et al, 1996; Cleutjens et al,
1997). The ARE-I and -III elements are high-affinity binding sites
accounting for 80% of promoter activity (Schuur et al, 1996;
Cleutjens et al, 1997).
Steroid hormone receptors are known to recognize common
hormone response elements (HREs). DNA binding analysis such
as DNAse protection and methylation interference studies of the
MMTV promoter shows nearly identical binding patterns for AR
and glucocorticoid receptor (GR) (Ahe et al, 1985; Truss and
Beato, 1993; Cairns et al, 1991). Similar studies with the tyrosine
aminotransferase (TAT) gene shows AR, GR and progesterone
receptor (PR) binding to the same HRE sequence in the gene.
Studies from our laboratory have shown that the breast carcinoma
cell lines T-47D and BT-474, upon induction with androgens and
progestins, produce large amounts of PSA (Zarghami et al, 1997).
Therefore, it would appear that the PR receptor mediates its effect
through the androgen response elements in the PSA gene.
Because the PSA gene is an important clinical marker and its
widespread expression in various organs is under regulation by
steroid hormones, expression and regulation of the PSA gene in
breast cancer might signify the involvement of the gene during
progression, pathogenesis or under certain stages of the disease. In
fact, there are already indications that PSA is a marker of prognosis
and risk assessment in breast cancer patients (Yu et al, 1995; Sauter
et al, 1996). In an earlier study by Tsuyuki et al (1997), 1.4 kb of
the PSA promoter region displayed multiple base substitutions and
deletions with no mutations in the cDNA of the gene. Because the
enhancer element of the PSA gene appears to be critical for gene
expression, we were interested to characterize the coding and
promoter/enhancer region of the PSA gene from a subset of breast
tumours and also breast carcinoma cell lines for which the PSA and
PR and oestrogen receptor (ER) status was known. This would
allow us to systematically determine any mutations that are
frequently observed in the gene, especially in the HREs, and to
correlate them with the presence or absence of PSA.
MATERIALS AND METHODS
Breast tumours
Approximately 1500 breast tumour cytosolic extracts were
screened for PSA protein levels using a highly sensitive immuno-
fluorometric assay (Ferguson et al, 1996). These tumours were
also analysed for oestrogen receptor (ER) and progesterone
receptor (PR) protein levels as part of routine investigations. Out
of the 1500 tumours, nine tumours were selected for this study that
displayed variable amounts of PSA protein ranging from 0 ng g–1
to 9291 ng g–1 with corresponding low and high levels of
oestrogen and progesterone receptor (Table 1).
Cell lines
We examined four breast carcinoma cell lines which were cultured
as described previously (Zarghami et al, 1997). The receptor status
and inducibility of PSA production by steroid hormones in these
cell lines is shown in Table 2.
Genomic DNA extraction
Genomic DNA from tumours was extracted according to the stan-
dard proteinase K digestion and phenol/chloroform extraction
method (Maniatis et al, 1982). Briefly, the tumour samples were
pulverized with a prechilled mortar and pestle to a fine powder.
The powdered tissue was digested with digestion buffer containing
100 mM sodium chloride, 10 mM tris-HCl, pH 8, 25 mM EDTA,
pH 8, 0.5% sodium dodecyl sulphate, 0.1 mg ml–1 proteinase K
and incubated at 50°C with shaking for 12–18 h. For extraction of
nucleic acids, the digested samples were extracted with an equal
volume of phenol/chloroform/isoamyl alcohol and centrifuged for
Table 1 Concentration of PSA in breast tumour extracts
Tumour no. ER PR PSA
(fmol mg–1) (fmol mg–1) (ng g–1)
1 0 0 5248
2 531 674 0
3 3 5 7141
4 112 0 9291
5 634 0 348
6 98 1230 0
7 389 436 0
8 410 374 0
9 32 689 0
Table 2 Breast carcinoma cell lines used in this study and their ability to
produce PSA
Cell line ER status PR status PSA production
T-47D + + Relatively large amounts of PSA
produced after stimulation with
androgens, progestins,
glucocorticoids
and mineralocorticoids, but not
oestrogens
MCF-7 + + Traces of PSA produced after
stimulation by glucocorticoids and
progestins, but not androgens or
oestrogens
BT-474 + + Relatively large amounts of PSA
produced after stimulation by
androgens, progestins,
mineralocorticoids and smaller
amounts by glucocorticoids and
oestrogens
ZR-75-1 ++ No PSA production after
stimulation with any steroid
hormones1596 S Majumdar and EP Diamandis
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10 min at 1700 g. The aqueous phase was then transferred to a new
tube and the DNA precipitated with 0.5 volumes of 7.5 M ammo-
nium acetate and two volumes of ethanol.
Genomic DNA isolated from lymphocytes was extracted as
follows: red blood cells were lysed with 30 ml of lysis buffer
(155 mM ammonium chloride, 10 mM potassium bicarbonate,
1m M disodium EDTA, pH 8.2), incubated on ice for 15 min and
centrifuged at 2000 r.p.m. for 10 min. The supernatant was
discarded and 10 ml of lysis buffer was added and centrifugation
repeated as above. Three millilitres of nuclei lysis buffer was
added and digested overnight at 37°C. Three millilitres of sterile
water and 3 ml of 6 M sodium chloride was added and mixed
vigorously to precipitate proteins and spun at 13 000 r.p.m. for
3 min. The DNA was precipitated by adding two volumes of 100%
ethanol. The DNA was spooled out and transferred to a microfuge
tube and dissolved in TE buffer (10 mM tris-HCl, 0.2 mM disodium
EDTA, pH 7.5).
Polymerase chain reaction (PCR) amplification
PCR amplification of the PSA exons were performed as follows:
one cycle of denaturation at 94°C for 5 min followed by denatura-
tion at 94°C for 30 s, annealing at 65°C for 30 s and extension at
72°C for 30 s, repeated for 30 cycles. The final cycle was an exten-
sion for 5 min at 72°C. The primer sequences used for the amplifi-
cation of the individual exons are listed in Table 3. Sequencing
primers for these fragments are shown in Table 4.
PCR amplification of the PSA promoter and enhancer elements
was carried out with nine specific pairs of primers as shown in
Table 5, and sequencing primers are presented in Table 6.
Fragment numbers 1, 2, 3, 5 and 6 were amplified essentially as
described above. Fragment numbers 4, 7 and 9 were similarly
amplified with an annealing temperature of 60°C.
Sequencing
The five exons and the promoter and enhancer elements of the
PSA gene were PCR amplified from the various breast tumours
Table 3 PCR primers for the amplification of the PSA exons
Exon Primer Sequencea PCR fragment Coordinatesb
name size (basepairs)
1 1 ATGGGGAGGGCCTTGGTCAG 281 539 to  558
1¢ TGTCTGGGCTGGGGTGCTG 801 to  819
2 2 CCCCCGTGTCTTTTCAAACC 407 1856 to 1875
2´ GCCTCCCCATGTGACCTGA 2244 to 2262
3 3 CCCAACCCTGTGTTTTTCTC 501 3634 to 3653
3¢ GGCCCTCCTCCCTCAGA 4118 to 4134
4 4 GGAGGAGGGGACAGGACTC 302 4094 to 4112
4¢ TCTAGACCCCAGCCCAGAAT 4376 to 4395
5 5 GTCGGCTCTGGAGACATTTC 374 5558 to 5577
5¢ AACTGGGGAGGCTTGAGTC 5613 to 5631
aAll sequences are given in the 5¢–3¢ direction.  bRefers to nucleotide numbers based on Genbank accession no. M27274.
Table 4 Primers used for the sequencing of the PSA exons
Exon Primer Sequencea Coordinatesb
name
1 1s GAGTCCTGGGGAATGAA 586 to  602
1as GAAAGAGCCTCAGCTTG 774 to  790
2 2s TCCATCTCCTATCCGAG 1887 to 1903
2as CAGAACTTTCCCTCTCT 2225 to 2241
3 3s TCTCTTTTGGAGCCTCC 3666 to 3682
3as AGGAGTCCTGTCCCCTC 4098 to 4114
4 4s TGAGGGAGGAGGCCCAA 4120 to 4136
4as TTAAGGTCCCCACTCAC 4360 to 4376
5 5s TCCAAAGCTGGGAACTG 5586 to 5602
5as GGCCTGGTCATTTCCAA 5894 to 5910
aAll sequences are given in the 5¢–3¢ direction. bRefers to the nucleotide numbers based on Genbank accession no. M27274.
s, sense; as, antisense.Mutations in the PSA gene in breast cancer and breast carcinoma cell lines 1597
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and cell lines as described above and sequenced directly. The PCR
reaction products were purified by Qiagen quick PCR purification
columns (Qiagen, Clatsworth, CA, USA) to remove excess
primers and deoxynucleosides. The details of the different
oligonucleotides used for sequencing of the PSA exons and 5¢
flanking sequences are outlined in Tables 4 and 6 respectively. The
sequencing primers were Cy5 fluorescent dye labelled at the 5¢
end. Sequencing on the purified PCR fragments was performed
using the Thermosequenase Cycle Sequencing protocol
(Amersham Life Sciences, Buckinghamshire, UK), the fragments
were then resolved on a 6% sequencing gel on the ALF Express
automated Sequencer (Pharmacia Biotech, Sweden). Sequencing
was performed on both strands of DNA. Any mutations identified
were further verified by additional PCR reactions followed by
sequencing.
RESULTS
Expression of the PSA gene in tumours with
undetectable PSA protein
The breast tumours selected for this study showed variable levels
of PSA expression associated with presence or absence of ER and
PR. To determine whether the tumours with 0 ng g–1 PSA
harboured any mutations in the coding region of the PSA gene,
the five PSA exons were PCR amplified with specific primers
(Table 3), and the PCR reactions were run on agarose gels. All the
PSA exons from all nine tumours and cell lines amplified effi-
ciently and to their correct sizes as determined by agarose gel
electrophoresis (Figure 1). The PCR amplified reactions were
then directly sequenced with Cy5-labelled primers (Table 4) to
determine any mutations. No abnormalities were observed in the
protein-coding portion of the gene. The PCR sequences were iden-
tical to the corresponding region of the PSA mRNA sequence
registered in GenBank (accession no. M27274). In three out of
nine tumours, a polymorphism was observed in exon 2 (Figure 2),
as also reported previously (Schulz et al, 1988; Lundwall, 1989;
Tsuyuki et al, 1997). This suggests that the coding region of the
PSA gene is not a target for mutations in breast cancer.
Table 5 Primer sequences used for the PCR amplification of the PSA
promoter and enhancer elements
Primer name Sequencea Coordinatesb
1 TTTCCCGGTGACATCGTG – 5768 to – 5751
1¢ CTCAAAGACCTCAGGCGTTTC – 5001 to – 5021
2 AAGAGATGACCTCTCAGGCTC – 5086 to – 5066
2¢ TGACTCAGGAGTCTCATGGAC – 4394 to – 4414
3 TTTGTGAATGCTGGCAGAG – 4432 to – 4413
3¢ CCTTTGAAATTCAAGAGGGTG – 3650 to – 3670
4 GGTCCCGATCGACTGTGTCTG – 3790 to – 3770
4¢ GCAGGCCACTCCCACCAG – 3082 to – 3099
5 CAGCCACCTGCCAACCGTAGA – 3135 to – 3115
5¢ TCTGAGCCAACATCAAAACAA – 2398 to – 2418
6 AAATTAGCTGGGCATGGTGCT – 2453 to – 2435
6¢ GTTTGGGATGGCATGGCTT – 1765 to – 1785
7 TAGAAACAGGGGAAGATTTTA – 1947 to – 1967
7¢ ATTACAGGTGCCCTGTG – 1078 to – 1094
8 CCGGGCGTGGTGGCAC – 1092 to – 1107
8¢ TCCCTGATCCCTGCACCACTC – 384 to  – 404
9 TTTCAGGAGCATGAGGAATAA – 426 to  – 446
9¢ CCCAGGAGCCCTATAAAAC – 12 to  – 30
aAll sequences are given in the 5¢–3¢ direction. bRefers to the nucleotide
numbers based on Genbank accession no. U37672.
Table 6 Primer sequences used for the sequencing of the PSA promoter
and enhancer elements
Primer name Sequencea (X = Cy5 label) Coordinatesb
1 X-TGACATCGTGGAAAGCAC – 5760
2 X-TCAGGAGACTGAGACCAT – 5448
3 X-TTAGCCAGGATGGTCTCA – 5457
4 X-TCAGGCGTTTCCCCTCAG – 5066
5 X-TGACCTCTCAGGCTCTGA – 5080
6 X-CTGCAGTTGGTGAGTGGT – 4730
7 X-AGAGACCATGACCACTAC – 4740
8 X-TCTCATGGACTCTGCCAG – 4422
9 X-TGCTGGCAGAGTCCATGA – 4424
10 X-CTTGCAAGATGATATCT – 4030
11 X-TCTGAGAGAGATATCATC – 4038
12 X-TTCAAGAGGGTGGACCCA – 3676
13 X-ACTGTGTCTGGCAGCACT – 3779
14 X-ACCTAATGGTTCCAGCCT – 3433
15 X-AAGGCAGAGGCTGGAACC – 3440
16 X-ACCAGAGGAGGATGGGCA – 3112
17 X-AACCGTAGAGCTGCCCAT – 3123
18 X-TCAATCCTATACCCAGCA – 2654
19 X-TTAGATAAAGTGCTGGGT – 2660
20 X-AAAACAAATCTATTTCCA – 2429
21 X-ATGGCTTTGGGATGGAAA – 2441
22 X-TTCCCTGGATTCATCCTG – 2086
23 X-TTCCTTTCCAGGATGAAT – 2094
24 X-ATGGTGCTGCATGCCTGT – 1795
25 X-AAGATTTTATCAAATTCT – 1955
26 X-TACCTCCACTGTTAACTC – 1527
27 X-TTTGCATGCCACCTTAAT – 1459
28 X-TTCTGGGTTCAAGTGATT – 1048
29 X-TGAACCCAGAAGGCAGA – 1041
30 X-AATAACCCCCCACTCCTT – 652
31 X-AATTCCACATTGTTTGCT – 632
32 X-TAGATCCTTTGCACTCCA – 337
33 X-AAGGATCTAGGCACGTGA – 328
34 X-TGGGGCTGGGGAGCCTCC – 11
aAll sequences are given in the 5¢–3¢ direction. bRefers to the nucleotide
numbers based on Genbank accession no. U37672.1598 S Majumdar and EP Diamandis
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Mutations in the upstream regulatory element of the
PSA gene in breast cancer
To examine whether the variable expression of the PSA protein is
determined at the level of regulation, the PSA promoter and
enhancer element were PCR amplified using nine different pairs of
primers (primers designed from the wild-type gene sequence as
published by Schuur et al, 1996) encompassing 5.8 kb of upstream
sequences from all the tumours and breast cancer cell lines 
(Table 5). A schematic representation of the PSA promoter and
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Figure 1 Agarose gel electrophoresis of PCR-amplified PSA exons 1–5.
PCR was performed as described in the Materials and methods section. The
PCR reaction products were run on a 2% agarose gel stained with ethidium
bromide and viewed under UV light. The numbers on the top of the gel
represent the number of the exon. M represents the 1-kb molecular weight
standard. The length of the PCR products are 281 bp (exon 1), 407 bp (exon
2), 501 bp (exon 3), 302 bp (exon 4) and 374 bp (exon 5)
Figure 2 PSA exons amplified by PCR were sequenced on the ALF Express automated Sequencer using Cy5-labelled primers. A polymorphism was
observed in exon 2 in three breast tumours corresponding to the sequence published by Schulz et al (1988). The filled arrows indicate the beginning and end of
the exon. The open arrows indicate the sites of the polymorphism. In the wild-type sequence, the nucleotides are T and A, and in the polymorphic sequences












Figure 3 Schematic representation of the PSA gene promoter and
enhancer elements. The position of the AREs (androgen response elements)
and the respective coordinates are indicated. The enhancer element is
located between positions – 3.7 kb and – 5.3 kb. The transcription start site is






Figure 4 PCR amplification of the promoter and enhancer elements of the
PSA gene. The PCR products were run on a 2% agarose gel stained with
ethidium bromide. The 5.8-kb PSA 5¢-flanking region was amplified using
nine pairs of PCR primers. Each fragment amplified was approximately
700–800 bp in length. The numbers above each lane represent the primer
pair used to amplify that fragment (details of primers and coordinates are
given in Table 4). M represents the 1-kb molecular weight markerMutations in the PSA gene in breast cancer and breast carcinoma cell lines 1599
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PCR products, each approximately 700–800 bases, were analysed
on agarose gels (Figure 4). PSA promoter and enhancer character-
ization was performed by DNA sequence analysis on both strands.
Each of the PCR-amplified fragments was directly sequenced
with specific Cy5-labelled primers (Table 6) on an automated
sequencer. We observed numerous deletions, insertions and point
mutations in comparison with the wild-type sequence in all the
breast tumours and cell lines. The distinct mutations in the various
tumours are shown in detail in Table 7 along with the corre-
sponding PSA, ER and PR protein levels in the tumour cytosols.
The mutations observed more than once in the tumours and cell
lines are outlined in Table 8. From previous studies by Schuur et al
(1996) and Cleutjens et al (1997), it is apparent that the ARE-I is a
critical regulatory element of the PSA gene. Interestingly, the
ARE-I in a proportion of breast tumours and in the breast carci-
noma cell line MCF-7 was observed to be frequently altered in the
half site.
DISCUSSION
The complex molecular mechanisms underlying the development
and progression of breast cancer are not very well understood.
Studies have uncovered genes that are responsible for familial and
sporadic breast cancer. Recently, we identified an important
prostatic tumour marker, which is also expressed in normal, hyper-
plastic and cancerous breast tissue. PSA or KLK3 appears to be a
favourable prognostic indicator for breast cancer (Yu et al, 1995).
This study is the first to demonstrate multiple mutations in the
enhancer element of the PSA gene in breast cancer.
To determine the molecular mechanism by which the PSA gene
is regulated in breast cancer, we selected tumours that expressed
variable levels of PSA protein and progesterone receptor. To deter-
mine whether tumours with undetectable PSA protein were associ-
ated with mutations in the PSA gene, we PCR amplified the five
PSA exons from genomic DNA extracted from the tumours and
analysed the PCR products by sequencing. This sequence analysis
revealed the absence of mutations in any of the five PSA exons.
These data agree with our previously published observations
regarding the mutational status of the PSA coding exons and a
small part of the proximal promoter of this gene (Tsuyuki et al,
1997). There are several other possible explanations for the aber-
rant PSA expression in the breast tumours and cell lines that we
analysed. An upstream regulator involved in the negative regula-
tion of the gene might result in low or undetected expression of the
PSA gene. A second possibility is that the PSA gene becomes
inactivated as the tumour either dedifferentiates or undergoes an
abnormal developmental programme. These explanations are not
mutually exclusive because changes in control of expression of the
PSA gene by upstream factors may result from an altered develop-
mental programme.
Another important possibility is that an epigenetic change such
as methylation could have inactivated the locus. In breast cancer,
methylation of 5¢ sequences in other genes is associated with loss
of activity of these genes (Ottaviano et al, 1994; Graff et al, 1995;
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Figure 5 A representative example of the wild-type ARE-I (A) and the mutated ARE-I (B) which was observed in four tumours and in the breast cancer cell
line MCF-7. A point mutation (G–A) was observed in the half site of the ARE-I element between –156 and –170 in the PSA promoter. The mutation in the lower
panel is indicated by a black triangle1600 S Majumdar and EP Diamandis
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Table 7 Novel mutations in the PSA gene promoter/enhancer elements in breast tumours and cell lines, found only once
Tumour/cell line ER PR PSA Mutations identifieda
1 0 0 5248 G–Ab – 3900
G–T – 2590
Insertion of G – 2821
2 531 674 0 C–T – 4759
A–C –  4279
T–A –  4002
Insertion of T – 2919
Insertion of G – 2916
Insertion of G – 2069
Insertion of CAA – 1908
4 112 0 9291 Deletion of G – 4774
Insertion of C  – 4768
G–A – 4606
Insertion of C  – 352
Deletion of A – 155
5 634 0 348 A–C – 4219
Insertion of T – 4066
A–G – 3927
Deletion of G – 2814
Deletion of C  – 2485
A–G – 155
6 98 1230 0 Insertion of C – 3882
G–C – 3798
A–C – 3147
Insertion of C  – 2810
C–T –  2619
Insertion of G – 2457
Insertion of G – 1762
Deletion of C – 1369
Insertion of C  – 692
T–G – 511
7 389 436 0 Insertion of G – 5581
Insertion of T – 5537
Insertion of G – 5117
T–G – 4579
A–C –  4272
Insertion of C – 2968
Deletion of A  – 2599
8 410 374 0 G–A – 5261
A–C – 4976
C–T –  4866
Insertion of G – 2939
Deletion of C – 2241
T–G – 1212
MCF-7 N/Ac N/A N/A Insertion of T – 5488




Deletion of A  – 206
T-47D N/A N/A N/A Insertion of T – 5503
Insertion of G – 319
BT-474 N/A N/A N/A Insertion of T  – 4038
A–G – 3316
Insertion of T – 3313
Insertion of G – 3278
Insertion of C – 3203
Deletion of GTG – 3190
ZR-75-1 N/A N/A N/A C–G – 5600
T–C – 5428
Deletion of A – 5169
A–C – 4733
Deletion of G – 3611
C–G – 2942
aRefers to nucleotide numbers in Genbank accession no. U37672. bIndicates that the mutation is in the core enhancer. cN/A, not
applicable; see Table 2.Mutations in the PSA gene in breast cancer and breast carcinoma cell lines 1601
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of epigenetic event, one that results in regional alteration in chro-
matin structure other than just primary gene silencing. There is
evidence, for example, of patients that show oestrogen receptor
negativity due to methylation of the ER receptor (Ottaviano et al,
1994).
To examine the possibility that the PSA gene in breast cancer
is under regulation by upstream sequences, we analysed by
sequencing the promoter and the enhancer elements of the PSA
gene. On PCR amplification of the entire 5.8 kb of regulatory
sequences, we identified multiple mutations in the promoter and
the enhancer elements. These mutations are presented in Tables 7
and 8. In Table 7, we show mutations that occur only once. The
alterations include point mutations, small insertions and small
deletions. The single appearance of these genomic changes in
tumours and cell lines precludes us to correlate their presence with
the expression pattern of PSA, but one striking feature is the
frequency of their appearance. Each tumour or cell line has, on
average, about six unique nucleotide changes in this region. We
speculate that this portion of the genome appears to be a target for
multiple genetic changes, contrary to our observation that the
coding region of this gene is devoid of such changes. Further func-
tional studies will be necessary to establish whether these and the
other changes observed indeed affect the expression of the PSA
gene and in which direction.
In Table 8, we report mutations that occurred more than once in
either the tumours or the cell lines. Regarding the association of
these mutations with PSA protein expression, we have the
following comments. The mutation at position –5703 occurs in
two tumours that are both progesterone receptor negative and they
overexpress PSA. This change may be associated with aberrant
PSA gene overexpression that does not require progesterone
receptors. The mutation at position –5700 is among the most
prevalent, found in eight out of nine tumours examined. This
mutation occurs in both steroid hormone receptor (SHR)-positive
and -negative tumours and also in PSA(+) and PSA(–) tumours.
Strikingly, the appearance of this mutation is always associated
with the insertion of C at position –5619 with the exception of
tumour 7 and the cell line T-47D, suggesting that these two genetic
changes may be linked. The mutations in position –5444 (insertion
of T) as well as the mutation at –3900 are seen, similarly to the
mutation at –5703, in the two tumours that are receptor negative
and at the same time overexpress PSA (tumour numbers 1 and 3).
Of possible importance is that one of these mutations (–3900)
occurs within the recently identified core enhancer of the PSA
gene (Schuur et al, 1996; Cleutjens et al, 1997). The importance of
these three mutations (–5703, –5444, –3900) in the aberrant
expression of the PSA gene in tumours that have no progesterone
receptors needs further investigation.
Among the other mutations, we found no consistency between
their presence and PSA expression pattern. For example, the muta-
tions at position –5389, –5378, –4848, –4845, –3898, –3813,
–2669 and –1905 are associated with tumours that either over-
express or do not express. Similarly, the mutations at positions
–4271 and –4269 appeared only in one tumour and one cell line
and could not be correlated with PSA expression.
Among all mutations identified, the one at position –158, which
affects the ARE-I, appears to be the most important. It has been
previously shown (Henntu et al, 1992; Young et al, 1992) that PSA
expression is responsive to androgen stimulation. The regulatory
mechanism includes binding of the androgen-activated androgen
receptor to the PSA promoter, which contains ARE-I. The ARE-I
and ARE-III elements are high-affinity binding sites responsible
for > 80% of the promoter/enhancer activity, and a mutational
change in ARE-I will probably affect promoter activity and PSA
expression as shown previously (Schuur et al, 1996; Cleutjens et
al, 1997). The ARE-I mutation was found in four out of nine
tumours indicating that it is prevalent. Three of these tumours are
steroid hormone receptor positive and yet produce no PSA at all.
Also, the MCF-7 cell line, which is steroid hormone receptor
positive and does not produce PSA upon androgen stimulation,
harbours this mutation as well. We speculate that the presence of
this mutation may be associated with loss of androgen-regulated
PSA expression in breast tumours.
One tumour (tumour 4), which harbours the ARE-I mutation
and is PR(–), produced more PSA than any other tumour in our
series. A careful evaluation of the mutational status of this tumour,
Table 8 Mutations commonly observed in breast tumours and cell lines
Coordinatesa Mutations Tumours/cell lines
– 5703 G–T 1, 3
– 5700 A–T 1, 2, 4, 5, 6, 7, 8, 9, MCF-7
– 5619 Insertion of C 1, 2, 4, 5, 6, 8, 9, MCF-7,
T-47D
– 5444 Insertion of T 1, 3
– 5389 G–T 4, 5, 6
– 5378 Insertion of CAACT 4, 5, 7
– 4848 Deletion of T (mutation in core enhancer) 1, 2
– 4845 Insertion of G 1, 2, 3
– 4271 G–C 4, MCF-7
– 4269 A–C 4, MCF-7
– 3900 G – A (mutation in core enhancer) 1, 3
– 3898 G–A 5, 6
– 3813 C–A 5, 7
– 2669 to – 2745 Deletion of 76 bases 1, 2, 3
– 1905 Deletion of A 2, 3
– 158 G–A (ARE-I mutation) 4, 6, 8, 9, MCF-7
aRefers to nucleotide numbers based on Genbank accession no. U37672.1602 S Majumdar and EP Diamandis
British Journal of Cancer (1999) 79(9/10), 1594–1602 © Cancer Research Campaign 1999
and of tumour 5 which has a similar receptor status and also over-
expresses PSA, reveals that they both harbour a mutation at
nucleotide –155, which lies just outside the consensus sequence of
ARE-I (–170 to –156). In the case of tumour 4, the nucleotide at
position –155 (A) is deleted and is followed by G. In the case of
tumour 5, the mutation changes an A to G. These observations,
suggesting aberrant PSA expression associated with genetic
changes inside or just outside the ARE-I of the PSA gene
promoter, need further investigation with functional studies.
In conclusion, we have presented evidence that the coding
region of the PSA gene is not mutated in either breast tumours
or breast carcinoma cell lines. We also show that the
promoter/enhancer region of this gene, encompassing approxi-
mately 5.8 kb of upstream sequence, is a target for numerous
mutations, including 16 different mutational hotspots (appearing
more than once). Among these hotspots, two appeared in eight out
of nine or seven out of nine tumours and one hotspot, within the
ARE-I, was found in four out of nine tumours. We are currently
pursuing the significance of these mutations and their effect on the
expression of the PSA gene by site-directed mutagenesis, followed
by functional analysis in transfection studies. We are also exam-
ining in a large series of tumours and normal tissues the prevalence
of the ARE-I mutation and its association with breast cancer
prognosis or susceptibility.
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